Monopar Therapeutics Inc. (MNPR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Monopar Therapeutics Inc. on February 27, 2025, covering events occurring on February 27 and February 28, 2025. The filing addresses significant changes in the Company's executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and executive compensation arrangements.
Material Changes
- Departure of CFO: Karthik Radhakrishnan's employment terminated on February 28, 2025. He ceased serving as Chief Financial Officer, principal financial officer, and principal accounting officer.
- Appointment of New CFO: The Board of Directors appointed Quan Vu as the new Chief Financial Officer, principal accounting officer, and principal financial officer, effective March 3, 2025.
- Compensation Package: Mr. Vu's appointment includes an annual salary of $350,000, a target bonus of up to 35% of base salary, and stock options to purchase 25,000 shares of Common Stock.
Outlook, Risks, and Management Commentary
The filing details Mr. Vu's extensive background, including over 20 years of experience in corporate finance, investment banking, and public company leadership. His recent roles include Venture Partner at ZhongMei Capital (Oct 2024-Feb 2025), CFO of Ocugen, Inc. (2023), and leadership positions at 180 Life Sciences Corp. and Opiant Pharmaceuticals. The stock options granted vest 6/48ths on September 3, 2025, with the remainder vesting monthly thereafter, expiring 10 years from the grant date. No related party transactions were reported.
Key Facts for Investor Verification
- Confirm the effective date of the CFO transition (March 3, 2025) and the interim financial reporting status during the transition.
- Verify the vesting schedule and exercise price of the 25,000 stock options granted to the new CFO.
- Review the Company's cash position to ensure it can support the new executive compensation package and ongoing operations.
- Monitor for any subsequent filings regarding the departure of Mr. Radhakrishnan, such as severance agreements or exit interviews, which are not detailed in this 8-K.